Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells

Molecular Carcinogenesis

Volumn 16, Issue 1, 1996, Pages 20-31

  Ho, Yuan Soon ^a,b   Wang, Ying Jan ^a   Lin, Jen Kun ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

apoptosis; nitric oxide; p21 WAF1 CIP1; p53 tumor suppressor

Indexed keywords

NITRIC OXIDE; PROTEIN P51; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

3T3 CELLS; ADENOCARCINOMA; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MICE; NITRIC OXIDE; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0029942290     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.0.CO;2-S     Document Type: Article

References (63)

1. Bredt DS, Snyder SH. Nitric oxide: A physiologic messenger molecule. Annu Rev Biochem 63:175-195, 1994.
2. Arroyo PL, Hatch-Pigott V, Mower HF, et al. Mutagenicity of nitric oxide and its inhibition by antioxidants. Mutat Res 281:193-202, 1992.
3. Nguyen TD, Brunson CL, Crespi BW, et al. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89:3030-3034, 1992.
4. Isomura KM, Chikahira KT, Hamada K. Induction of mutations and chromosome aberrations in lung cells following in vivo exposure of rats to nitrogen oxides. Mutat Res 136:119-125, 1984.
5. Wink DA, Kasprzak KS, Maragos CM, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254:1001-1003, 1991.
6. Christoph S, William MR III, Shen JC, et al. Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-strand DNA. Carcinogenesis 15:2899-2903, 1994.
7. Jorge EA, Shijun C, Romeo BM, et al. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150:5080-5085, 1993.
8. M'hammed S, Vongthip S, Ariette A. Nitric oxide synthase induces macrophage death by apoptosis. Biochem Biophys Res Commun 191:503-508, 1993.
9. Mebmer UK, Ankarcrona M, Nicotera P, et al. p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355:23-26, 1994.
10. Wang JM, Lin-Shiau SY, Lin JK. Relaxation of rat thoracic aorta by N-nitroso compounds and nitroprusside and their modifications of nucleic acid bases through release of nitric oxide. Biochem Pharmacol 454:819-825, 1993.
11. Lin JK, Kuo ML. Nitroso-N-2-fluorenylacetamide: A new direct-acting mutagen and teratogen. Mutat Res 201:117-126, 1988.
12. Ho YS, Lin JK. N-Nitroso-2-acetylaminofluorene: A direct-acting hepatocarcinogen induced hepatocellular carcinoma in Sprague-Dawley rats. Jpn J Cancer Res 85:794-800, 1994.
13. Ho YS, Cheng HT, Wang YJ, et al. P53 gene mutational spectra in hepatocellular carcinomas induced by 2-acetylaminofluorene and N-nitroso-2-acetylaminofluorene in rats. Mol Carcinog 13:182-190, 1995.
14. Wang YJ, Ho YS, Lo MJ, et al. Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and aging. Chem-Biol Interact 94:135-145, 1995.
15. Edwards JC, Ignarro U, Hyman AL, et al. Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther 228:3-42, 1983.
16. DeRobertis FR, Craven PA. Calcium-independent modulation of cyclic GMP and activation of guanylate cyclase activation by nitrosamines. Science 193:897-899, 1976.
17. Gruetter CA, Barry BK, McNamara DB, Kadowitz PJ, Ignarro LJ. Coronary arterial relaxation and guanylate cyclase activation by cigarette smoke, N'-nitrosonornicotine and nitric oxide. J Pharmacol Exp Ther 214:9-15, 1980.
18. DeLeo AB, Jay G, Appella E, et al. Detection of transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76:2420-2424, 1979.
19. Crawford LV, Pim DC, Gurney EG, et al. Detection of a common feature in several human cell lines - a 53,000-dalton protein. Proc Natl Acad Sci USA 78:41-45, 1981.
20. Lane DP, Crawford LV. Tiantigen is bound to a host protein in SV40 transformed cells. Nature 278:261-263, 1979.
21. Linzer DIH, Levine AJ. Characterization of 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52, 1979.
22. Oren M, Maltzman W, Levine AJ. Post translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol 1:101-110, 1981.
23. Reich IMC, Oren M, Levine AJ, Two distinct mechanisms regulate the levels of a cellular antigen, p53. Mol Cell Biol 3:2143-2150, 1983.
24. Rogel A, Popliker M, Webb CG, et al. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissue, embryos, and tumors. Mol Cell Biol 5:2851-2855, 1985.
25. Baker SJ, Markowitz S, Fearon ER, et al. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915, 1990.
26. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093, 1989.
27. Zambetti GP, Bargonetti J, Walker K, et al. Wild-type p53 mediates positive regulation of gene expression through a specific DMA sequence element. Genes Dev 6:1143-1152, 1992.
28. El-Deiry WS, Tokino K, Velculescu VE, et al. WAF1 a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993.
29. El-Deiry WS, Harper JW, O'Connor PK, et al. WA1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994.
30. Dulic V, Kaufmann WK, Wilson SJ, et al. P53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994.
31. Harper JW, Adamy GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816, 1993.
32. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366:707-710, 1993.
33. Xiangwei WJ, Henri B, David O, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993.
34. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing pS3 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-591, 1992.
35. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993.
36. Barak Y, Juven T, Haffner R, et al. MDM2 expression is induced by wild-type p53 activity. EMBO J 12:461-468, 1993.
37. Zauberman A, Barak Y, Ragimov N, et al. Sequence-specific DNA binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 12:2799-2808, 1993.
38. Painter RB, Young BR. Radiosensitivity in ataxia-telangiectasia: A new explanation. Proc Natl Acad Sci USA 77:7315-7317, 1980.
39. Weinert TA, Hartwell LH, The RAD9 gene controls the cell cycle response to DNA damage in saccharomyces cerevisiae. Science 241:317-322, 1988.
40. Diller L, Kassel Nelson CE, Gryka MA, et al. P53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10:5772-5781, 1990.
41. Mercer WE, Shields MT, Amin M, et al. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA 87:6166-6170, 1990.
42. Michael BK, Onyinye O, David S, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
43. Michael F, Christel H, Gerhard B. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA damaging agents. Oncogene 8:307-318, 1993.
44. Warren M, Linda C. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689-1694, 1984.
45. Clarke AR, Purdie CA, Harrison RG, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852, 1993.
46. Lowe SW, Schmitt EM, Smith SW, et al. P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-848, 1993.
47. Semple TU, Quinn LA, Woods LK, et al. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxic model. Cancer Res 38:1345-1355, 1978.
48. Aden DP, Fogel A, Plotkin S, et al. Controlled synthesis of HBs Ag in a differentiated human liver carcinoma-derived cell line. Nature 282:615-616, 1979.
49. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499, 1980
50. Darlington GJ, Kelly JH, Buffone GJ. Growth and hepatospecific gene expression of human hepatoma cells in a defined medium In Vitro Cell Dev Biol 23:349-354, 1987.
51. Bressac B, Galvin KM, Liang TJ, et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:1973-1977, 1990.
52. Niewolik D, Vojtesek B, Kovarik J. P53 derived from human tumor cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 10:881-890, 1995.
53. Tsuda H, Kushi A, Yoshida D, et al. Chromosomal aberrations and sister chromatid exchanges induced by gaseous nitrogen oxide in cultured Chinese hamster cells. Mutat Res 89:303-309, 1981.
54. Gurney EG, Harrison RO, Fenno J, et al. Monoclonal antibodies against simian virus 40 T antigens: Evidence for distinct subclasses of large T antigen and for similarities among nonviral T antigens. J Virol 34:752-763, 1980.
55. Ball RK, Siegl B, Quellhorts S, et al. Monoclonal antibodies against simian virus 40 nuclear large T tumor antigen: Epitope mapping, papovavirus cross-reaction and cell surface staining. EMBO J 3:1485-1491, 1984.
56. Schneider C, Newman RA, Sutherland DR, et al. A one-step purification of membrane proteins using a high efficiency immunomatrix. J Biol Chem 257:10766-10769, 1982.
57. Levine AJ. The tumor suppressor genes. Ann Rev Biochem 62:623-651, 1993.
58. Scott WL, Stephan B, Andrea M, et al. P53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
59. Smith ML, Chen IT, Zhan Q, et al. Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage. Oncogene 10:1053-1059, 1995.
60. Xia F, Wang YH, Tsang NM, et al. Altered p53 status correlates with differences in sensitivity to radiation-induced mutation and apoptosis in two closely related human lymphoblast lines. Cancer Res 55:12-15, 1995.
61. Roselli F, Ridet A, Soussi T, et al. P53-dependent pathway of radio-induced apoptosis is altered in Fanconi anemia. Oncogene 10:9-17, 1995.
62. Hoeijmakers JHJ. How relevant is the Escherichia coli uvrABC model for excision repair in eukaryotes? J Cell Sci 100:687-691, 1991.
63. Stewart N, Hicks GG, Parakevas F, et al. Evidence for a second cell cycle block at G2/M by p53. Oncogene 10:109-115, 1995.